ReNeuron makes shifts and additions to senior team

UK-based stem cell therapy company ReNeuron has announced a number of board and senior management changes.

Sharon Grimster has been named as general manager for Wales. Grimster has worked at the firm as interim chief development officer since last year and will now take on further responsibility for the development of ReNeuron's in-house manufacturing capability when it relocates its operations to South Wales later this year.

Grimster has extensive experience in advanced biologics development as has served in senior developments roles at businesses including F-star, Antisoma and Celltech.

Dr Randolph Corteling has been promoted to head of research from his current role of head of cell biology after joining in 2007. 

Olav Hellebø, CEO of ReNeuron, commented: “I am delighted to welcome Sharon Grimster and Randolph Corteling to the senior management team at ReNeuron.  Their skills and experience will be invaluable as ReNeuron continues its transition into a fully fledged clinical development business.”

Additionally, John Berriman, a non-executive director since 2011, has taken on the role of chairman after Bryan Morton stepped down.

Mark Docherty, a non-executive director since 2005, with step down from the role in September while John Sinden, chief scientific officer (CSO) and co-founder of ReNeuron and a board member since the beginning, will also step down from the board. Sinden will continue in his role as CSO.

Concerning the board alteration, Hellebø added: “I would also like to thank Bryan Morton and Mark Docherty for the immense contribution they have both made to the company's success over their respective long tenures on the board and to welcome John Berriman to the role of chairman.”